Healthcare / BiotechnologyTaipei Exchange
$24.40
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-98.3M · quality 67.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
17/100
F
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$5.2B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-10.2%
↓Gross Margin
34.4%
↓Debt/Equity
0.13
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+2.0%
FCF CAGR
—
FCF margin
-14.9%
FCF / Net income
0.31x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $368.9M · net income $-176.8M · FCF $-54.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $368.9M | $368.9M | $382.7M | $362.8M | $347.7M |
| Net Income | $-176.8M | $-176.8M | $-205.7M | $-319.8M | $-54.5M |
| EBITDA | $-96.0M | $-96.0M | $-130.7M | $-271.7M | $-68.0M |
| EPS | — | — | -1.14 | -2.21 | -0.39 |
| Gross Margin | 34.4% | 34.4% | 30.8% | 29.1% | 35.2% |
| Operating Margin | -60.4% | -60.4% | -65.9% | -65.7% | -42.8% |
| Net Margin | -47.9% | -47.9% | -53.7% | -88.1% | -15.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.13 | 0.13 | 0.13 | 0.07 | 0.12 |
| Current Ratio | 10.42 | 10.42 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-54.9M | $-54.9M | $-172.4M | $-98.3M | $-41.0M |
| Returns | |||||
| ROE | -10.2% | -10.2% | -10.6% | -38.3% | -15.3% |
| Valuation | |||||
| P/B | 2.70 | 2.70 | 3.63 | — | — |
| Growth & Yield | |||||
| Revenue Growth | -3.6% | -3.6% | 5.5% | 4.3% | — |
| EPS Growth | — | — | 48.4% | -466.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-30.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.14 → n/d
Residual
-30.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.